Corrigendum: A first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia. (Ann Pharmacother. (2015), 49, (1057-1067), 10.1177/1060028015588555);Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia

Annals of Pharmacotherapy

Volumn 49, Issue 9, 2015, Pages 1057-1067

  Buie, Larry W ^a   Pecoraro, Joshua J ^a   Horvat, Troy Z ^a   Daley, Ryan J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

B cell acute lymphoblastic leukemia; BiTE; blinatumomab; Blincyto

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BLINATUMOMAB; CD19 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIGEN BINDING; APHASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL PHARMACOLOGY; CONCENTRATION AT STEADY-STATE; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONVULSION; CYTOKINE RELEASE; DISORIENTATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EMBASE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MEDLINE; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SEPSIS; SPEECH DISORDER; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; TREMOR; TUMOR LYSIS SYNDROME; URINARY EXCRETION; VOMITING; WHEEZING; ACUTE DISEASE; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; IMMUNOLOGY; MOUSE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; MICE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 84940214289     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015621161     Document Type: Erratum

References (79)

1. National Cancer Institute. SEER Stat Fact Sheets: Leukemia. http://seer.cancer.gov/statfacts/html/leuks.html. Accessed December 30, 2014.
2. D.PulteL.JansenA.Gondos. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014;9:e85554.
3. Y.ZhouM.J.YouK.H.Young. Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol. 2012;43:1347-1362.
4. N.GokbugetD.HoelzerTreatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009;46:64-75.
5. J.M.RoweG.BuckA.K.Burnett. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760-3767.
6. C.LinkerL.DamonC.RiesW.NavarroIntensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2464-2471.
7. J.M.RoweA.H.GoldstoneHow I treat acute lymphocytic leukemia in adults. Blood. 2007;110:2268-2275.
8. V.BachanovaD.WeisdorfUnrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review. Bone Marrow Transplant. 2008;41:455-464.
9. A.H.GoldstoneS.M.RichardsH.M.Lazarus. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-1833.
10. S.J.FormanJ.M.RoweThe myth of the second remission of acute leukemia in the adult. Blood. 2013;121:1077-1082.
11. M.BruggemannN.GokbugetM.KnebaAcute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol. 2012;39:47-57.
12. M.BruggemannT.RaffT.Flohr. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116-1123.
13. M.BruggemannT.RaffM.KnebaHas MRD monitoring superseded other prognostic factors in adult ALL?Blood. 2012;120:4470-4481.
14. M.BruggemannA.SchrauderT.Raff. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24:521-535.
15. T.RaffN.GokbugetS.Luschen. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109:910-915.
16. O.SpinelliB.PerutaM.Tosi. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612-618.
17. O.SpinelliM.TosiB.Peruta. Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6:e2014062.
18. B.WassmannH.PfeiferM.Stadler. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106:458-463.
19. M.J.BorowitzM.DevidasS.P.Hunger. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood. 2008;111:5477-5485.
20. N.J.GouldenC.J.KnechtliR.J.Garland. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol. 1998;100:235-244.
21. C.J.KnechtliN.J.GouldenJ.P.Hancock. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998;92:4072-4079.
22. C.J.KnechtliN.J.GouldenJ.P.Hancock. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol. 1998;102:860-871.
23. P.GameiroF.Y.MortuzaA.V.HoffbrandL.ForoniMinimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Haematologica. 2002;87:1126-1134.
24. F.Y.MortuzaM.PapaioannouI.M.Moreira. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094-1104.
25. B.PatelL.RaiG.Buck. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148:80-89.
26. C.NyvoldH.O.MadsenL.P.Ryder. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002;99:1253-1258.
27. A.K.FieldingS.M.RichardsR.Chopra. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944-950.
28. D.NagorsenP.A.BaeuerleImmunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011;317:1255-1260.
29. P.A.BaeuerleP.KuferR.BargouBiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. 2009;11:22-30.
30. R.BargouE.LeoG.Zugmaier. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-977.
31. B.MlecnikG.BindeaF.PagesJ.GalonTumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011;30:5-12.
32. L.ZhangJ.R.Conejo-GarciaD.Katsaros. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
33. X.ZhuangX.XiaC.Wang. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol. 2010;18:24-28.
34. J.GalonA.CostesF.Sanchez-Cabo. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
35. B.E.WahlinB.SanderB.ChristenssonE.KimbyCD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13(2, pt 1):388-397.
36. S.FerroneT.L.WhitesideTumor microenvironment and immune escape. Surg Oncol Clin N Am. 2007;16:755-774, viii.
37. A.PezzuttoB.DorkenP.S.RabinovitchJ.A.LedbetterG.MoldenhauerE.A.ClarkCD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol. 1987;138:2793-2799.
38. S.R.FrankelP.A.BaeuerleTargeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17:385-392.
39. C.A.HurwitzM.R.LokenM.L.Graham. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood. 1988;72:299-307.
40. S.RaponiM.S.De ProprisS.Intoppa. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52:1098-1107.
41. D.NagorsenP.KuferP.A.BaeuerleR.BargouBlinatumomab: a historical perspective. Pharmacol Ther. 2012;136:334-342.
42. T.DreierP.A.BaeuerleI.Fichtner. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol. 2003;170:4397-4402.
43. D.NagorsenR.BargouD.RuttingerP.KuferP.A.BaeuerleG.ZugmaierImmunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50:886-891.
44. B.SchlerethC.QuadtT.Dreier. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother. 2006;55:503-514.
45. B.WuY.HijaziA.WolfC.BrandlY.N.SunM.ZhuPharmacokinetics (PK) of blinatumomab and its clinical implications. J Clin Oncol. 2013;31(15):abstract 3048.
46. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Reviews: Application 125557Orig1s000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125557Orig1s000ClinPharmR.pdf. Accessed January 19, 2015.
47. A.Von StackelbergG.ZugmaierR.Handgretinger. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood. 2013;122(21):abstract 70.
48. Amgen. Blincyto (blinatumomab) [package insert]. http://www.onyx.com/file.cfm/723/docs/blincyto_pi_hcp_english.pdf. Accessed May 11, 2015.
49. M.S.ToppN.GokbugetG.Zugmaier. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134-4140.
50. Y.HijaziM.KlingerA.Schub. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J Clin Oncol. 2013;31(15):abstract 3057.
51. M.KlingerC.BrandlG.Zugmaier. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226-6233.
52. M.S.ToppP.KuferN.Gokbuget. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493-2498.
53. M.S.ToppN.GokbugetG.Zugmaier. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185-5187.
54. M.S.ToppN.GokbugetA.S.Stein. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66.
55. P.SchlegelP.LangG.Zugmaier. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99:1212-1219.
56. A.von StackelbergF.LocatelliG.Zugmaier. Phase 1/2 study in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. Blood. 2014;124:2292.
57. M.ToppN.GoekbugetG.Zugmaier. Anti-CD19 BiTE(registered trademark) blinatumomab induces high complete remission rates in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia (ALL) including relapse after stem cell transplantation (SCT). Bone Marrow Transplant. 2013;48:S40-S41.
58. L.GoreF.LocatelliG.ZugmaierInitial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood. 2014;124:3703.
59. N.GokbugetH.DombretM.Bonifacio. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL) [abstract 379]. Paper presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco, CA.
60. National Cancer Institute. NCI guidelines for investigators. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf. Accessed April 7, 2015.
61. N.GokbugetH.KantarjianM.Bruggemann. An evaluation of molecular response in a phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) receiving treatment with the BiTE® antibody construct blinatumomab [abstract 3704]. Paper presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco, CA.
62. A.ViardotM.GoebelerG.Hess. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE®) antibody construct blinatumomab: primary analysis results from an open-label, phase 2 study [abstract 4460]. Paper presented at: American Society of Hematology Annual Meeting; December 6-9, 2014; San Francisco, CA.
63. C.BrandlC.HaasS.d’Argouges. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. 2007;56:1551-1563.
64. D.M.BarrettD.T.TeacheyS.A.GruppToxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26:43-49.
65. D.W.LeeR.GardnerD.L.Porter. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.
66. P.SchlegelP.LangG.Zugmaier. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99:1212-1219.
67. D.T.TeacheyS.R.RheingoldS.L.Maude. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154-5157.
68. S.A.GruppM.KalosD.Barrett. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.
69. S.M.HuangH.ZhaoJ.I.Lee. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther. 2010;87:497-503.
70. C.BargouG.ZugmaierN.Goekbuget. Prolonged leukemia free survival following blinatumomab (anti-cd19 bite(registered trademark)) treatment of patients with minimal residual disease (MRD) of b precursor all: updated results of a phase II study. Haematologica. 2010;95:250.
71. M.ToppN.GoekbugetA.S.Stein. Open-label, single-arm, multicenter confirmatory phase 2 study of the bite(registered trademark) antibody blinatumomab in patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia. Haematologica. 2014;99:258.
72. D.A.ThomasH.KantarjianT.L.Smith. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86:1216-1230.
73. E.TavernierJ.M.BoironF.Huguet. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907-1914.
74. A.OriolS.VivesJ.M.Hernandez-Rivas. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010;95:589-596.
75. N.GokbugetD.StanzeJ.Beck. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032-2041.
76. S.O’BrienD.ThomasF.Ravandi. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113:3186-3191.
77. M.KatoY.HorikoshiY.Okamoto. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant. 2012;47:1307-1311.
78. M.E.GoebelerA.ViardotP.Kufer. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-Hodgkin’s lymphoma. Hematol Oncol. 2013;31:197.
79. ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed February 15, 2015.